Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ME-344, an investigational drug candidate, is a novel inhibitor of mitochondrial oxidative phosphorylation (OXPHOS) is being investigated in combination with bevacizumab in relapsed metastatic colorectal cancer patients.
Lead Product(s): ME-344,Bevacizumab
Therapeutic Area: Oncology Product Name: ME-344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
ME-522 (voruciclib), an investigational selective oral CDK9 inhibitor, in combination with venetoclax (Venclexta®), a BCL2 inhibitor is being evaluated for the treatment of relapsed and refractory acute myeloid leukemia.
Lead Product(s): Voruciclib,Venetoclax
Therapeutic Area: Oncology Product Name: ME-522
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2024
Details:
ME-344 is a novel mitochondrial inhibitor targeting energy production through the OXPHOS pathway evaluating in combination with bevacizumab in patients with previously treated metastatic colorectal cancer.
Lead Product(s): ME-344,Bevacizumab
Therapeutic Area: Oncology Product Name: ME-344
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
Under the termination, Infinity has continued to prepare for the initiation of a planned global Phase 2 clinical trial evaluating IPI-549 (eganelisib) in head and neck squamous cell carcinoma.
Lead Product(s): Eganelisib,Nivolumab
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Infinity Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination July 24, 2023
Details:
IPI-549 (eganelisib) is a first-in-class, oral, once-daily, immuno-oncology candidate that selectively inhibits phosphoinositide-3-kinase gamma, which is investigated in Combination with Pembrolizumab in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN).
Lead Product(s): Eganelisib,Pembrolizumab
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Infinity Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
ME-522 (voruciclib) is an orally administered cyclin-dependent kinase 9 (“CDK9”) inhibitor with potential to treat Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies
Lead Product(s): Voruciclib,Venetoclax
Therapeutic Area: Oncology Product Name: ME-522
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
The Combination will create a company with a diverse product development pipeline led by a planned new global Phase 2 clinical trial evaluating IPI-549 (eganelisib) in head and neck squamous cell carcinoma (HNSCC)
Lead Product(s): Eganelisib,Pembrolizumab
Therapeutic Area: Oncology Product Name: IPI-549
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Infinity Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 23, 2023
Details:
ME-401 (zandelisib), a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with B-cell malignancies.
Lead Product(s): Zandelisib
Therapeutic Area: Oncology Product Name: ME-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
ME-401 (zandelisib), a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, treatment for patients with B-cell malignancies.
Lead Product(s): Zandelisib
Therapeutic Area: Oncology Product Name: ME-401
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Kyowa Kirin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
ME-401 (zandelisib), a selective PI3Kδ inhibitor, is an investigational cancer treatment being developed as an oral, once-daily, potential therapeutic option for patients with B-cell malignancies.
Lead Product(s): Zandelisib,Rituximab
Therapeutic Area: Oncology Product Name: ME-401
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kyowa Kirin
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022